N-[6-morpholin-4-yl-2-(2-pyridin-2-yl-ethoxy)-pyrimidin-4-ylmethylene]-N'-m-tolyl-hydrazine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[6-morpholin-4-yl-2-(2-pyridin-2-yl-ethoxy)-pyrimidin-4-ylmethylene]-N'-m-tolyl-hydrazine
• 英文别名: 3-methyl-N-[(E)-[6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-yl]methylideneamino]aniline
• 化学式: C₂₃H₂₆N₆O₂
• 分子量: 418.498
• InChiKey: RBDANGBZUKDDFG-KOEQRZSOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  31
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  84.8
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  2-[2-(pyridin-2-yl)-ethoxy]-4-(methoxycarbonyl)-6-(morpholin-4-yl)-pyrimidine 在 溶剂黄146 manganese(IV) oxide 、 sodium tetrahydroborate 作用下， 以 乙醇 、 甲苯 为溶剂， 反应 7.0h， 生成 N-[6-morpholin-4-yl-2-(2-pyridin-2-yl-ethoxy)-pyrimidin-4-ylmethylene]-N'-m-tolyl-hydrazine
  参考文献：
  名称：

  [EN] HETEROARYL-HYDRAZONE COMPOUNDS
  [FR] COMPOSES HETEROARYLE-HYDRAZONE

  摘要：

  公开号：

  WO2005046604A3

文献信息

• Heteroaryl-hydrazone compounds
  申请人：Ono Mitsunori

  公开号：US20050282809A1

  公开（公告）日：2005-12-22

  This invention relates to compounds having a formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, prodrug or polymorph thereof wherein X is —C(R g )═N-A. The invention also relates to methods of treating IL-12 overproduction-related disorders, methods of treating or preventing disorders related with excessive bone loss, methods for inhibiting osteoclast formation, and methods for treating or preventing a disorder associated with excessive bone resorption.

  本发明涉及具有以下公式（I）的化合物或其药学上可接受的盐，溶剂化合物，包合物，水合物，前药或多晶体，其中X为—C（Rg）═N-A。该发明还涉及治疗与IL-12过度产生相关的疾病的方法，治疗或预防与过度骨质流失相关的疾病的方法，抑制成骨细胞形成的方法以及治疗或预防与过度骨吸收相关的疾病的方法。
• Compositions and methods for modulating c-Rel-dependent cytokine production
  申请人：Lu Rongzhen

  公开号：US20050282232A1

  公开（公告）日：2005-12-22

  The present invention is directed to compositions and methods for modulating c-Rel-dependent cytokine production without materially altering the level of expression of NFκB and/or the amount of IκB. The present invention is also directed to screening for modulators of c-Rel activity as determined by assaying for altered subcellular localization of c-Rel but where the level of expression of NFκB and/or the amount of IκB is materially unaltered.
• Method for treating B cell regulated autoimmune disorders
  申请人：Foley Kevin

  公开号：US20070032493A1

  公开（公告）日：2007-02-08

  The invention relates to a method for treating B-cell regulated autoimmune disorders using compounds that modulate the activity of c-Rel.
• COMPOSITIONS AND METHODS FOR MODULATING C-REL-DEPENDENT CYTOKINE PRODUCTION
  申请人：Lu Rongzhen

  公开号：US20080227114A1

  公开（公告）日：2008-09-18

  The present invention is directed to compositions and methods for modulating c-Rel-dependent cytokine production without materially altering the level of expression of NFκB and/or the amount of IκB. The present invention is also directed to screening for modulators of c-Rel activity as determined by assaying for altered subcellular localization of c-Rel but where the level of expression of NFκB and/or the amount of IκB is materially unaltered.
• PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS
  申请人：Kostik Elena

  公开号：US20090163708A1

  公开（公告）日：2009-06-25

  This invention relates to a method of preparing mesylate salts of compounds that inhibit IL-12, IL-23 and/or IL-27 production.